 | Up a level |
Galle, Peter R; Kudo, Masatoshi; Llovet, Josep M; Finn, Richard S; Karwal, Mark; Pezet, Denis; Kim, Tae-You; Yang, Tsai-Sheng; Lonardi, Sara; Tomasek, Jiri; Phelip, Jean-Marc; Touchefeu, Yann; Koh, Su-Jin; Stirnimann, Guido; Liang, Kun; Ogburn, Kenyon D; Wang, Chunxiao; Abada, Paolo; Widau, Ryan C and Zhu, Andrew X (2021). Ramucirumab in patients with previously treated advanced hepatocellular carcinoma: Impact of liver disease aetiology. Liver international, 41(11), pp. 2759-2767. Wiley 10.1111/liv.14994
Finn, Richard C; De Toni, Enrico N; Chung Cheung Yau, Thomas; Yen, Chia-Jui; Hsu, Chih-Hung; Chan, Stephen L; He, Aiwu Ruth; Galle, Peter; Trojan, Jörg; Stirnimann, Guido; Baron, Ari; Rivera, Mirelis Acosta; Goyal, Lipika; Wang, Chunxiao; Abada, Paolo; Widau, Ryan; Zhu, Andrew X (November 2020). Ramucirumab for patients with advanced HCC and elevated alpha-fetoprotein following non-sorafenib-based therapy: interim results from phase 3 REACH-2 expansion cohort. In: SOHC 2020 - Swiss Oncology & Hematology Congress - 3rd; Online Conference. November 18 - 21, 2020.
Galle, Peter; Kudo, Masatoshi; Llovet, Josep M.; Finn, Richard; Karwal, Mark; Pezet, Denis; Kim, Tae-You; Yang, Tsai-Sheng; Zagonel, Vittorina; Tomasek, Jiri; Phelip, Jean-Marc; Touchefeu, Yann; Koh, Su-Jin; Stirnimann, Guido; Wang, Chunxiao; Ogburn, Kenyon; Abada, Paolo B.; Widau, Ryan; Zhu, Andrew (2020). Impact of baseline hepatitis B viremia and management on outcomes in advanced hepatocellular carcinoma and elevated alpha-fetoprotein: outcomes from REACH-2. Journal of hepatology, 73(S1), S386-S387. Elsevier 10.1016/S0168-8278(20)31264-2
